Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
TILs Demonstrate Improved PFS Vs Ipilimumab in Unresectable Melanoma
September 10th 2022A tumor-infiltrating lymphocyte therapy manufactured at various centers in the Netherlands Cancer Institute elicited a 50% reduction in the risk of progression or death vs ipilimumab in patients with stage IIIC/IV unresectable, treatment-refractory melanoma.
Read More
Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC
September 10th 2022First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.
Read More
Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma
June 7th 2022The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.
Read More
Radiotherapy Unnecessary for Some Luminal A Breast Cancers
June 7th 2022Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study.
Read More
Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC
June 5th 2022Treatment with fam-trastuzumab deruxtecan-nxki doubled progression-free survival and reduced the risk of death by 36% compared with physician's choice of chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer.
Read More
CT041 CAR T-cell Therapy Elicits Manageable Toxicity and Durable Response in Gastric/GEJ Cancer
June 5th 2022CT041, a Claudin18.2–specific CAR T-cell therapy, demonstrated a manageable safety profile in patients with previously treated, CLDN18.2-positive advanced gastric/gastroesophageal junction cancer, with a majority of patients achieving partial response or stable disease.
Read More
Trastuzumab Deruxtecan Remains Safe and Effective Option for Metastatic Breast Cancer
June 4th 2022Updated data from a safety analysis of the phase 3 DESTINY-Breast03 study confirmed the tolerability of trastuzumab deruxtecan among patients with with HER2-positive unresectable or metastatic breast cancer.
Read More
ctDNA Demonstrates Efficacy as Treatment-Decision Tool for Adjuvant Chemotherapy in Colon Cancers
June 4th 2022Guided approaches leveraging circulating tumor DNA status can reduce the number of patients who receive adjuvant chemotherapy without the risk of lowering recurrence-free survival rates for some patients with stage II colon cancer.
Read More
Glofitamab Demonstrates Durable Response in Heavily Pretreated Large B-Cell Lymphoma
June 4th 2022Glofitamab elicited an objective response rate of 51.6% when administered for a fixed duration among patients with patients with heavily pretreated, highly refractory large B-cell lymphoma, regardless of prior CAR T-cell therapy exposure, according to findings from a phase 2 expansion study.
Read More
Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma
June 3rd 2022Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.
Read More
CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma
April 25th 2022The novel allogeneic CAR-engineered natural killer cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.
Read More
Brain Metastases Are Now More Treatable in HER2+ Metastatic Breast Cancer
March 5th 2022The treatment of patients with HER2-positive metastatic breast cancer can now be tailored based on the presence of active central nervous system disease, due to substantial advances made in the past few years into small molecule inhibitors and macromolecule biologics.
Read More
Real-World Data Describe Eribulin Efficacy After Novel Agents for MBC
March 4th 2022Treatment with eribulin elicited an estimated 2-year overall survival rate of 53.6% for patients with metastatic breast cancer previously treated with atezolizumab or sacituzumab govitecan, according to real-world findings.
Read More
FDA Grants Orphan Drug Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
February 15th 2022The FDA has granted an orphan drug designation to the off-the-shelf natural killer cell therapy CYNK-101 as a potential treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Read More
FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
January 18th 2022The FDA has granted a fast track designation to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Read More
Real-World Evidence Supports Axi-Cel in Previously Excluded LBCL Populations
December 13th 2021Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma; however, adverse events were more common in some of these populations and ECOG performance status ≥2 was associated with worse outcomes and more adverse events, according to a large real-world study presented at the 2021 ASH Annual Meeting.
Read More
Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL
December 11th 2021The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Pamrevlumab May Address Unmet Need for Locally Advanced Pancreatic Cancer
February 17th 2021February 17, 2021 – Pamrevlumab, a first-in-class inhibitor of connective tissue growth factor activity, is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) in a phase 3 trial for patients with unresectable locally advanced pancreatic cancer, a population in need of new options.
Read More
Navitoclax Overcomes Ruxolitinib Resistance for Myelofibrosis
December 10th 2019Navitoclax plus ruxolitinib (Jakafi) showed clinically meaningful spleen responses and improvements in symptoms for patients with primary or secondary myelofibrosis, following the development of resistance to frontline ruxolitinib.
Read More